Several BET inhibitors are currently under investigation for the treatment of solid tumours and haematologic malignancies.4,8,26,27 These agents have shown varying degrees of clinical activity and tolerability across indications.28–34 In this study, the BET inhibitor RO6870810 had an acceptable and manageable safety profile in patients with NC and other solid tumours and DLBCL, which was confirmed in an expansion cohort enrolled at the recommended phase 2 dose of 0.65 mg/kg administered for 14 of every 21 days. The gene discussed is DNER; the disease is diffuse large B-cell lymphoma.